Aimed Bio KRX:0009K0KOSDAQ
에임드바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days7
DART filings, 7 days1
Articles tracked14since Sep 11
In Q2 2026, Aimed Bio reported revenue of ₩20.2bn, up 165.6% year on year, and operating profit of ₩8.5bn. Aimed Bio (에임드바이오) appeared in 7 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 27 with 7 articles. The most common catalyst was contracts & orders (8).
Filing signals Profit +50% Op. margin 20%+ Clinical trial filing Screener
Aimed Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩20.2bn | +165.6% | ₩8.5bn margin 42.2% | ₩10.9bn |
| Q1 2026 | ₩8.5bn | +437.5% | −₩4.0bn margin −46.6% | −₩2.0bn |
| Q4 2025 derived | ₩38.0bn | +233.0% | ₩25.5bn margin 67.2% | ₩34.9bn |
| Q3 2025 | ₩114m | +0.5% | −₩5.9bn | −₩5.2bn |
| Q2 2025 | ₩7.6bn | – | ₩2.2bn margin 29.5% | −₩23.6bn |
| Q1 2025 | ₩1.6bn | – | −₩1.1bn margin −71.5% | −₩1.1bn |
| Q4 2024 derived | ₩11.4bn | – | ₩8.4bn margin 74.1% | ₩7.1bn |
| Q3 2024 | ₩114m | – | −₩4.6bn | −₩2.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Aimed Bio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Aimed Bio news Korean headlines
-
Major에임드바이오, 베링거 ADC 임상 진입에 마일스톤 확보
1 more on this story · 1 outlets
- 에임드바이오, 베링거 ADC 임상 진입에 마일스톤 확보이데일리 · Oct 27 09:09
-
MajorBreaking에임드바이오, 베링거인겔하임서 ODS025 마일스톤 기술료 수령 예정…지난해 영업수익 10% 이상
1 more on this story · 1 outlets
- 에임드바이오, 獨 베링거인겔하임서 ‘ODS025’ 마일스톤 기술료 수령파이낸스투데이 · Oct 27 08:58